Download PDF
J Pediatr Intensive Care 2021; 10(04): 298-302
DOI: 10.1055/s-0040-1713614
Case Report

Lifesaving Treatment of Aortic Valve Staphylococcus aureus Endocarditis: Daptomycin and Early Surgical Therapy

Can Yilmaz Yozgat 
1   Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey
,
Selcuk Uzuner 
2   Department of Pediatric Critical Care Medicine, Bezmialem Vakif University, Istanbul, Turkey
,
Yasin Ay 
3   Department of Cardiovascular Surgery, Bezmialem Vakif University, Istanbul, Turkey
,
Hafize Otcu Temur 
4   Department of Radiology, Bezmialem Vakif University, Istanbul, Turkey
,
Burcu Bursal Duramaz 
5   Department of Pediatric Infectious Diseases, Bezmialem Vakif University, Istanbul, Turkey
,
Ozden Turel 
5   Department of Pediatric Infectious Diseases, Bezmialem Vakif University, Istanbul, Turkey
,
Muhittin Calim 
6   Department of Anesthesiology and Reanimation, Bezmialem Vakif University, Istanbul, Turkey
,
Nur Buyukpinarbasili 
7   Department of Pathology, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey
,
Yilmaz Yozgat 
8   Department of Pediatric Cardiology, Bezmialem Vakif University, Istanbul, Turkey
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Infective endocarditis (IE) is an uncommon infection in children. The recommended treatment for native valve endocarditis secondary to methicillin-susceptible Staphylococcus aureus infection is antistaphylococcal penicillins such as nafcillin or oxacillin. If the initial therapy fails in IE, it can lead to catastrophic results. Nowadays, daptomycin is the best alternative antimicrobial agent to treat children with severe infections, when standard antimicrobial therapy does not yield a result. Herein, in this article, we described a case of a 16-year-old boy who had aortic valve S. aureus endocarditis with septic embolization and stroke. The patient was successfully treated only with daptomycin as well as surgical therapy in the early phase of the infection.

Keywords

infective endocarditis - Staphylococcus aureus - open cardiac surgery - daptomycin - pediatric intensive care unit

Note

Permission was granted by the parents and patient to publish the case report.


Authors' Contributions

All authors participated in creating content for the manuscript, editing, and provided final approval for submission. No undisclosed authors contributed to the manuscript.




Publication History

Received: 11 March 2020

Accepted: 13 May 2020

Article published online:
30 July 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova NN. Trends in infective endocarditis in California and New York state, 1998-2013. JAMA 2017; 317 (16) 1652-1660
    CrossrefPubMedGoogle Scholar
  • 2 Irdem A, Baspinar O, Kervancioglu M, Sahin DA, Kilinc MA. Retrospective evaluation of patients with infective endocarditis [in Turkish]. Pediatr Inf 2012; 6: 127-132
    CrossrefPubMedGoogle Scholar
  • 3 Baddour LM, Wilson WR, Bayer AS. et al; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 2005; 111 (23) e394-e434
    CrossrefPubMedGoogle Scholar
  • 4 Habib G, Lancellotti P, Antunes MJ. et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36 (44) 3075-3128
    CrossrefPubMedGoogle Scholar
  • 5 Fowler Jr VG, Boucher HW, Corey GR. et al; S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus . N Engl J Med 2006; 355 (07) 653-665
    CrossrefPubMedGoogle Scholar
  • 6 Guleri A, Utili R, Dohmen P. et al. Daptomycin for the treatment of infective endocarditis: results from European Cubicin(®) Outcomes Registry and Experience (EU-CORE). Infect Dis Ther 2015; 4 (03) 283-296
    CrossrefPubMedGoogle Scholar
  • 7 Yozgat CY, Uzuner S, Yesilbas O, et al. Williams syndrome presenting with intractable Staphylococcus aureus endocarditis. Indian J Pediatr 2020. Doi: 10.1007/s12098-020-03207-0
    PubMed
  • 8 Ardura MI, Mejías A, Katz KS, Revell P, McCracken Jr GH, Sánchez PJ. Daptomycin therapy for invasive gram-positive bacterial infections in children. Pediatr Infect Dis J 2007; 26 (12) 1128-1132
    CrossrefPubMedGoogle Scholar
  • 9 Bradley J, Glasser C, Patino H. et al. Daptomycin for complicated skin infections: a randomized trial. Pediatrics 2017; 139 (03) e20162477
    CrossrefPubMedGoogle Scholar
  • 10 Garazzino S, Castagnola E, Di Gangi M. et al; SITIP Daptomycin Study Group. Daptomycin for children in clinical practice experience. Pediatr Infect Dis J 2016; 35 (06) 639-641
    CrossrefPubMedGoogle Scholar
  • 11 Karaci AR, Aydemir NA, Harmandar B. et al. Surgical treatment of infective valve endocarditis in children with congenital heart disease. J Card Surg 2012; 27 (01) 93-98
    CrossrefPubMedGoogle Scholar
  • 12 Hickey EJ, Jung G, Manlhiot C. et al. Infective endocarditis in children: native valve preservation is frequently possible despite advanced clinical disease. Eur J Cardiothorac Surg 2009; 35 (01) 130-135
    CrossrefPubMedGoogle Scholar